March 07, 2014
1 min read

China regulatory agency approves novel glaucoma surgical device

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The China Food and Drug Administration has granted marketing approval for the IOPtiMate system developed by IOPtima., a subsidiary of BioLight Israeli Life Sciences Investments, according to a press release.

The IOPtiMate system allows eye surgeons to perform CO2 laser-assisted sclerectomy surgery, which reduces elevated IOP in glaucoma patients by thinning the sclera of the eye, which restores the natural fluid percolation without penetrating the globe, the release said.